ADJUVANT HORMONE THERAPY ELIGIBILITY OF PREMENOPAUSAL WOMEN WITH ER+ BREAST CANCER
Adjuvant endocrine therapy of premenopausal patients with ER+ breast cancer typically consists in administration of tamoxifen for 5 years. However, in cases of high risk of disease recurrence there is a need to suppress (inhibit) function of the ovaries as the main generators of estrogen stimulating growth and progression of the disease, typically using agonists of gonadotropinreleasing hormone. As a result of the onset of drug-induced menopause it becomes possible to use with GnRH agonists not only tamoxifen but also aromatase inhibitors with enhanced antineoplastic activity.